oral glp 1 drugs in development GLP-1 Receptor Agonist Market Size & Analysis, 2026-2033 The Landscape Of GLP-1 Receptor

Cost-effectiveness analyses must consider both direct medication costs and potential savings from improved outcomes, including reduced diabetes complications, decreased healthcare utilization, and potential cardiovascular benefits

Nagendra, L., BG, H., Sharma, M., & Dutta, D

Diabetes Alzheimers Dement

doi: 10.1093/ibd/izad268 178 YangM.JiangZ.ZhouL.ChenN.HeH.LiW.et al

SGLT2 inhibitors Empagliflozin: Empagliflozin is a novel SGLT2 inhibitor, the underlying mechanisms of which include ameliorating hyperglycemia, preventing the development of endothelial dysfunction, reducing oxidative stress, and improving metabolic profiles